^
Association details:
| Biomarker: | NTRK3 mutation + TMB-H |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
Published date:
11/29/2023
Excerpt:
Notably, the mOS of patients with NTRK3 MT and high TMB was significantly prolonged compared to that of WT patients (mOS: NA vs. 14.00 months, HR = 0.29, 95%CI 0.09–0.93; log-rank P = 0.026) (Fig. 2I).
DOI:
https://doi.org/10.1186/s12890-023-02707-x
